rs149513065
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 1P and 0B. PP3
The NM_020975.6(RET):c.3191T>C(p.Met1064Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000142 in 1,614,192 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.3191T>C | p.Met1064Thr | missense_variant | Exon 20 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RET | ENST00000355710.8 | c.3191T>C | p.Met1064Thr | missense_variant | Exon 20 of 20 | 5 | NM_020975.6 | ENSP00000347942.3 | ||
RET | ENST00000615310.5 | c.*1361T>C | 3_prime_UTR_variant | Exon 17 of 17 | 5 | ENSP00000480088.2 | ||||
RET | ENST00000683007.1 | n.4154T>C | non_coding_transcript_exon_variant | Exon 16 of 16 |
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152232Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251476Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135920
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461842Hom.: 0 Cov.: 32 AF XY: 0.0000110 AC XY: 8AN XY: 727212
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152350Hom.: 0 Cov.: 32 AF XY: 0.0000671 AC XY: 5AN XY: 74504
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia, type 2 Uncertain:2
This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1064 of the RET protein (p.Met1064Thr). This variant is present in population databases (rs149513065, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of RET-related conditions (PMID: 7581377, 14633923, 27525386). ClinVar contains an entry for this variant (Variation ID: 161359). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on RET function (PMID: 9047383, 9502784). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This missense variant replaces methionine with threonine at codon 1064 of the RET protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have reported conflicting evidence of this variant's impact on transforming and kinase activity (PMID: 9047383, 9502784). This variant has been reported in an individual affected with medullary thyroid cancer (PMID: 27525386) and individuals affected with Hirschsprung disease (PMID: 14633923, 22174939, 22395866). This variant has been identified in 4/251476 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:2
- -
The p.M1064T variant (also known as c.3191T>C), located in coding exon 20 of the RET gene, results from a T to C substitution at nucleotide position 3191. The methionine at codon 1064 is replaced by threonine, an amino acid with similar properties. This variant has previously been reported in individuals affected with Hirschsprung disease (So MT et al. PLoS ONE 2011 Dec; 6(12):e28986; Attié T et al. Hum. Mol. Genet. 1995 Aug; 4(8):1381-6; Jannot AS et al. Eur. J. Hum. Genet. 2012 Sep; 20(9):917-20; Garcia-Barceló M et al. Clin Chem, 2004 Jan;50:93-100), as well as medullary thyroid cancer and pheochromocytoma (Sherman S et al. Cancer 2016 Dec;122(24):3856-3864; Ambry internal data). However, this variant has been detected in multiple individuals with no reported features of RET-associated disease (Ambry internal data). Functional studies using co-transfection with a constitutively activated MEN2A form of RET have shown this variant has minimal biological effect (Pelet A et al. J. Clin. Invest. 1998 Mar; 101(6):1415-23). Another study evaluated the effects of this alteration on binding various domains of the adaptor protein Shc, and found that p.M1064T binds three domains equally well as wild-type; but demonstrates a 30-40% reduction in binding affinity for the PTB domain of Shc (JLorenzo MJ et al. Oncogene 1997 Feb; 14(7):763-71). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
Hirschsprung disease Uncertain:1
- -
Multiple endocrine neoplasia type 2A;C0025269:Multiple endocrine neoplasia type 2B;C0031511:Pheochromocytoma;C1833921:Familial medullary thyroid carcinoma;C3888239:Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
not provided Uncertain:1
PP3 -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at